Drugs Made In America Acquisition Corp. (DMAA)

Drugs Made In America Acquisition Corp. is a blank check company formed to effect a merger, share exchange, asset acquisition, or similar business combination with one or more businesses, with an intended focus on the pharmaceutical industry. It has no significant operations of its own and maintains capital in a trust account until a suitable target is identified and the transaction completed.

Market
Nasdaq
Sector
Financial Services
Trend
Strong uptrend
Last close
10.76 (+0.09% on the day)
MA50
10.7
MA200
10.54
52-week range
10.25–10.76
Market cap
261M USD
P/E
59.72
Dividend yield
0%
Data as of
2026-09-04
Quarterly revenue and earnings, millions of USD
QuarterRevenueYoY %EarningsYoY %
Q1 202501.3
Q2 202502.3
Q3 202502.2
Q4 202500.2
Q1 20260257.1%

All markets — KeepWinning global stock screener

Other companies on Nasdaq: Willow Lane Acquisition Corp. II (WLII), BRBI BR Partners S.A. (BRBI), FACT II Acquisition Corp (FACT), One Stop Systems, Inc. (OSS), Anavex Life Sciences Corp. (AVXL), TRG Latin America Acquisitions Corp. (TRGS)